A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+T-Cells to Recognition by Cytotoxic T-Lymphocytes

PLoS Pathogens

Volumn 12, Issue 4, 2016, Pages

  Jones, R Brad ^a,b,c   Mueller, Stefanie ^b   O’Connor, Rachel ^a   Rimpel, Katherine ^a   Sloan, Derek D ^d   Karel, Dan ^a   Wong, Hing C ^e   Jeng, Emily K ^e   Thomas, Allison S ^a,c   Whitney, James B ^a,f   Lim, So Yon ^f   Kovacs, Colin ^g,h   Benko, Erika ^g   Karandish, Sara ^c   Huang, Szu Han ^c   Buzon, Maria J ^a   Lichterfeld, Mathias ^a   Irrinki, Alivelu ^d   Murry, Jeffrey P ^d   Tsai, Angela ^d   Yu, Helen ^d   Geleziunas, Romas ^d   Trocha, Alicja ^a   Ostrowski, Mario A ^h,i   Irvine, Darrell J ^b,j,k   Walker, Bruce D ^a,j   more..

^a HARVARD UNIVERSITY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d GILEAD SCIENCES   (United States)

^e ALTOR BIOSCIENCE CORPORATION   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g Maple Leaf Medical   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^k Massachusetts Institute of Technology Cambridge   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALT 803; ANTIVIRUS AGENT; GAMMA INTERFERON; HEXAMETHYLENEBISACETAMIDE; HISTONE DEACETYLASE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; PANOBINOSTAT; ROMIDEPSIN; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; VIRUS PROTEIN; VORINOSTAT; ALT-803; PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL CLONING; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMIC BIOSENSOR; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; POLYMERASE CHAIN REACTION; VIRAL CLEARANCE; VIRUS LATENCY; VIRUS TRANSCRIPTION; DRUG EFFECTS; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNOLOGY; VIROLOGY; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; POLYMERASE CHAIN REACTION; PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84964870083     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005545     Document Type: Article

References (62)

1. Rueda S, Law S, Rourke SB, (2014) Psychosocial, mental health, and behavioral issues of aging with HIV. Curr Opin HIV AIDS9: 325–331. doi: 10.1097/COH.000000000000007124824890
2. Arseniou S, Arvaniti A, Samakouri M, (2014) HIV infection and depression. Psychiatry Clin Neurosci68: 96–109. doi: 10.1111/pcn.1209724552630
3. Katz IT, Ryu AE, Onuegbu AG, Psaros C, Weiser SD, et al. (2013) Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc16: 18640. doi: 10.7448/IAS.16.3.1864024242258
4. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, et al. (1995) In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med1: 1284–1290. 7489410
5. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A94: 13193–13197. 9371822
6. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science278: 1295–1300. 9360927
7. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science278: 1291–1295. 9360926
8. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med5: 512–517. 10229227
9. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, et al. (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood115: 925–935. doi: 10.1182/blood-2009-08-23918619880495
10. Deeks SG, (2012) HIV: Shock and kill. Nature487: 439–440. doi: 10.1038/487439a22836995
11. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF, (2014) New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med20: 425–429. doi: 10.1038/nm.348924658076
12. Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, Wightman F, Lewin SR, et al. (2013) Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother9: 993–1001. doi: 10.4161/hv.2380023370291
13. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, et al. (2009) Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem284: 6782–6789. doi: 10.1074/jbc.M80789820019136668
14. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses25: 207–212. doi: 10.1089/aid.2008.019119239360
15. Mohammadi P, di Iulio J, Munoz M, Martinez R, Bartha I, et al. (2014) Dynamics of HIV latency and reactivation in a primary CD4+ T cell model. PLoS Pathog10: e1004156. doi: 10.1371/journal.ppat.100415624875931
16. Saleh S, Wightman F, Ramanayake S, Alexander M, Kumar N, et al. (2011) Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology8: 80. doi: 10.1186/1742-4690-8-8021992606
17. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, et al. (2014) Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog10: e1004071. doi: 10.1371/journal.ppat.100407124722454
18. Blazkova J, Chun TW, Belay BW, Murray D, Justement JS, et al. (2012) Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis206: 765–769. doi: 10.1093/infdis/jis41222732922
19. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, et al. (2015) Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest125: 1901–1912. doi: 10.1172/JCI8014225822022
20. Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M, Jr.et al. (2014) Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A111: 7078–7083. doi: 10.1073/pnas.140287311124706775
21. Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, et al. (2014) Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog10: e1004473. doi: 10.1371/journal.ppat.100447325393648
22. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature487: 482–485. doi: 10.1038/nature1128622837004
23. Irvine DJ, Purbhoo MA, Krogsgaard M, Davis MM, (2002) Direct observation of ligand recognition by T cells. Nature419: 845–849. 12397360
24. Lassen KG, Bailey JR, Siliciano RF, (2004) Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol78: 9105–9114. 15308706
25. Graf EH, Pace MJ, Peterson BA, Lynch LJ, Chukwulebe SB, et al. (2013) Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]. PLoS One8: e71879. doi: 10.1371/journal.pone.007187923951263
26. Pace MJ, Graf EH, Agosto LM, Mexas AM, Male F, et al. (2012) Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog8: e1002818. doi: 10.1371/journal.ppat.100281822911005
27. Jones RB, Garrison KE, Mujib S, Mihajlovic V, Aidarus N, et al. (2012) HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. J Clin Invest122: 4473–4489. doi: 10.1172/JCI6456023143309
28. Garrison KE, Jones RB, Meiklejohn DA, Anwar N, Ndhlovu LC, et al. (2007) T cell responses to human endogenous retroviruses in HIV-1 infection. PLoS Pathog3: e165. 17997601
29. Sahu GK, Lee K, Ji J, Braciale V, Baron S, et al. (2006) A novel in vitro system to generate and study latently HIV-infected long-lived normal CD4+T-lymphocytes. Virology355: 127–137. 16919704
30. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, et al. (2007) Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood110: 201–210. 17371945
31. Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, et al. (2014) Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog10: e1004287. doi: 10.1371/journal.ppat.100428725122219
32. Lehrman G, Ylisastigui L, Bosch RJ, Margolis DM, (2004) Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. J Acquir Immune Defic Syndr36: 1103–1104. 15247565
33. Wang FX, Xu Y, Sullivan J, Souder E, Argyris EG, et al. (2005) IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest115: 128–137. 15630452
34. Novis CL, Archin NM, Buzon MJ, Verdin E, Round JL, et al. (2013) Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1/2 stimulation. Retrovirology10: 119. doi: 10.1186/1742-4690-10-11924156240
35. Klichko V, Archin N, Kaur R, Lehrman G, Margolis D, (2006) Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J Virol80: 4570–4579. 16611917
36. Choudhary SK, Archin NM, Margolis DM, (2008) Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis197: 1162–1170. doi: 10.1086/52952518419522
37. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, et al. (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity36: 491–501. doi: 10.1016/j.immuni.2012.01.01422406268
38. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, et al. (2013) Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell155: 540–551. doi: 10.1016/j.cell.2013.09.02024243014
39. Pollack R (2015) Patient-derived defective HIV-1 proviruses containing large internal deletions can be transcribed and translated. Towards an HIV Cure Symposium. Vancouver.
40. Jayakumar A, Castilho TM, Park E, Goldsmith-Pestana K, Blackwell JM, et al. (2011) TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia). PLoS Negl Trop Dis5: e1204. doi: 10.1371/journal.pntd.000120421695103
41. Asprodites N, Zheng L, Geng D, Velasco-Gonzalez C, Sanchez-Perez L, et al. (2008) Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J22: 3628–3637. doi: 10.1096/fj.08-10827418587008
42. Hernandez-Ruiz J, Salaiza-Suazo N, Carrada G, Escoto S, Ruiz-Remigio A, et al. (2010) CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists. PLoS Negl Trop Dis4: e871. doi: 10.1371/journal.pntd.000087121072232
43. Ahmad A, Ahmad R, Iannello A, Toma E, Morisset R, et al. (2005) IL-15 and HIV infection: lessons for immunotherapy and vaccination. Curr HIV Res3: 261–270. 16022657
44. Chehimi J, Marshall JD, Salvucci O, Frank I, Chehimi S, et al. (1997) IL-15 enhances immune functions during HIV infection. J Immunol158: 5978–5987. 9190952
45. D'Offizi G, Gioia C, Corpolongo A, Martini F, Paganelli R, et al. (2007) An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects. Int J Immunopathol Pharmacol20: 473–485. 17880761
46. Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, et al. (2014) Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One9: e96705. doi: 10.1371/journal.pone.009670524896845
47. Mueller YM, Bojczuk PM, Halstead ES, Kim AH, Witek J, et al. (2003) IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood101: 1024–1029. 12393488
48. Stephan MT, Moon JJ, Um SH, Bershteyn A, Irvine DJ, (2010) Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med16: 1035–1041. doi: 10.1038/nm.219820711198
49. White L, Krishnan S, Strbo N, Liu H, Kolber MA, et al. (2007) Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV). Blood109: 3873–3880. 17192392
50. Wong HC, Jeng EK, Rhode PR, (2013) The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8 T cells into innate-like effector cells with antitumor activity. Oncoimmunology2: e26442. 24404427
51. Xin KQ, Hamajima K, Sasaki S, Tsuji T, Watabe S, et al. (1999) IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine17: 858–866. 10067692
52. Xu W, Jones M, Liu B, Zhu X, Johnson CB, et al. (2013) Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res73: 3075–3086. doi: 10.1158/0008-5472.CAN-12-235723644531
53. Rosenberg SA, (2014) IL-2: the first effective immunotherapy for human cancer. J Immunol192: 5451–5458. doi: 10.4049/jimmunol.149001924907378
54. Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, et al. (2015) Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature517: 381–385. doi: 10.1038/nature1405325561180
55. Lee SM, Joo YD, Seo SK, (2009) Expression and Function of TLR2 on CD4 Versus CD8 T Cells. Immune Netw9: 127–132. doi: 10.4110/in.2009.9.4.12720157599
56. Sung JA, Lam S, Garrido C, Archin N, Rooney CM, et al. (2015) Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J Infect Dis212: 258–263. doi: 10.1093/infdis/jiv02225589335
57. Zhu X, Marcus WD, Xu W, Lee HI, Han K, et al. (2009) Novel human interleukin-15 agonists. J Immunol183: 3598–3607. doi: 10.4049/jimmunol.090124419710453
58. Han KP, Zhu X, Liu B, Jeng E, Kong L, et al. (2011) IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine56: 804–810. doi: 10.1016/j.cyto.2011.09.02822019703
59. Mathios D, Park CK, Marcus WD, Alter S, Rhode PR, et al. (2015) Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int J Cancer.
60. Seay K, Church C, Zheng JH, Deneroff K, Ochsenbauer C, et al. (2015) In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice. J Virol89: 6264–6274. doi: 10.1128/JVI.00563-1525833053
61. Bosque A, Famiglietti M, Weyrich AS, Goulston C, Planelles V, (2011) Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathog7: e1002288. doi: 10.1371/journal.ppat.100228821998586
62. Messi M, Giacchetto I, Nagata K, Lanzavecchia A, Natoli G, et al. (2003) Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol4: 78–86. 12447360